Bexarotene safe treatment for early-stage CTCL

Article

Washington - Bexarotene gel appears to be an effective and well-tolerated monotherapy when used as first-line treatment for early-stage cutaneous T-cell lymphoma, Madeleine Duvic, M.D., reported at the annual meeting of the American Academy of Dermatology.

Related Videos
Related Content

4 For 4 Sessions With Raj Chovatiya, MD, PhD, Present Range of Dermatology Challenges and Opportunities

September 27th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Overview of Maui Derm NP+PA Fall 2023

September 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Retirement “Red Zone”: What You Need to Know to Score Financially

September 27th 2023

POLL: Are You Attending Maui Derm NP+PA Fall 2023?

September 26th 2023

4 For 4 Sessions With Raj Chovatiya, MD, PhD, Present Range of Dermatology Challenges and Opportunities

September 27th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Overview of Maui Derm NP+PA Fall 2023

September 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Retirement “Red Zone”: What You Need to Know to Score Financially

September 27th 2023

POLL: Are You Attending Maui Derm NP+PA Fall 2023?

September 26th 2023

4 For 4 Sessions With Raj Chovatiya, MD, PhD, Present Range of Dermatology Challenges and Opportunities

September 27th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Overview of Maui Derm NP+PA Fall 2023

September 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Retirement “Red Zone”: What You Need to Know to Score Financially

September 27th 2023

POLL: Are You Attending Maui Derm NP+PA Fall 2023?

September 26th 2023
© 2023 MJH Life Sciences

All rights reserved.